Bridgeway Capital Management’s Fate Therapeutics FATE Stock Holding History

Bridgeway Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$500K	Hold	185,000	–	–	0.01%	849
2026 Q1	$222K	Buy	185,000 +50,000	+37%	+$60.9K	﹤0.01%	1012
2025 Q4	$133K	Buy	135,000 +35,000	+35%	+$42K	﹤0.01%	1089
2025 Q3	$126K	Buy	100,000 +75,000	+300%	+$80.9K	﹤0.01%	1080
2025 Q2	$28K	Buy	+25,000	New	+$29.1K	﹤0.01%	1154
2018 Q2	–	Sell	-202,000	Closed	-$1.97M	–	1429
2018 Q1	$1.97M	Sell	202,000 -54,000	-21%	-$517K	0.02%	596
2017 Q4	$1.56M	Hold	256,000	–	–	0.02%	666
2017 Q3	$1.01M	Buy	256,000 +6,000	+2%	+$20.4K	0.01%	841
2017 Q2	$810K	Hold	250,000	–	–	0.01%	903
2017 Q1	$1.14M	Hold	250,000	–	–	0.01%	766
2016 Q4	$628K	Hold	250,000	–	–	0.01%	988
2016 Q3	$780K	Sell	250,000 -144,537	-37%	-$351K	0.01%	903
2016 Q2	$671K	Sell	394,537 -80,000	-17%	-$145K	0.01%	928
2016 Q1	$854K	Buy	474,537 +250,000	+111%	+$515K	0.01%	831
2015 Q4	$757K	Buy	224,537 +130,100	+138%	+$547K	0.01%	882
2015 Q3	$503K	Buy	94,437 +57,437	+155%	+$392K	0.01%	1022
2015 Q2	$239K	Buy	+37,000	New	+$221K	﹤0.01%	1315

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bridgeway Capital Management's FATE Position: Q2 2026 in Review

Bridgeway Capital Management held its Fate Therapeutics (FATE) position steady in Q2 2026 at 185,000 shares worth $500K. The position accounts for 0.01% of the portfolio, ranked #849.

Bridgeway Capital Management first reported a position in FATE in Q2 2015 and has held it in 17 quarters since. The position peaked at $1.97M in Q1 2018. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Bridgeway Capital Management held 185,000 shares of Fate Therapeutics worth $500K as of Q2 2026.
Bridgeway Capital Management left its Fate Therapeutics share count unchanged in Q2 2026.
Fate Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #849 holding.
Bridgeway Capital Management first reported a position in Fate Therapeutics in Q2 2015 and has held it in 17 quarters since.
Bridgeway Capital Management's Fate Therapeutics position peaked at $1.97M in Q1 2018.
155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.